Sri LankaTuberculosis profile
Population  2015 21 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.2 (0.93–1.4) 5.6 (4.5–6.9)
Mortality (HIV+TB only) 0.011 (<0.01–0.02) 0.06 (0.03–0.09)
Incidence  (includes HIV+TB) 13 (9.7–18) 65 (47–86)
Incidence (HIV+TB only) 0.043 (0.028–0.062) 0.21 (0.13–0.3)
Incidence (MDR/RR-TB)** 0.089 (0–0.19) 0.43 (0–0.92)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.66 (0.34–0.98) 4.2 (2–6.4) 4.8 (2.3–7.4)
Males 0.59 (0.36–0.82) 8.1 (5.9–10) 8.7 (6.3–11)
Total 1.2 (0.84–1.7) 12 (10–15) 13 (9.7–18)
TB case notifications, 2015  
Total cases notified 9 575
Total new and relapse 9 305
          - % tested with rapid diagnostics at time of diagnosis 3%
          - % with known HIV status 84%
          - % pulmonary 71%
          - % bacteriologically confirmed among pulmonary 69%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 69% (52–96)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.09 (0.06–0.13)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 25 <1%
          - on antiretroviral therapy 17 68%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  43
(0–93)
Estimated % of TB cases with MDR/RR-TB 0.54% (0–1.3) 1.7% (0.64–3.7)  
% notified tested for rifampicin resistance 13% 75% 1 635
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 15, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 13, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 84% 8 980
Previously treated cases, excluding relapse, registered in 2014 63% 168
HIV-positive TB cases, all types, registered in 2014 63% 19
MDR/RR-TB cases started on second-line treatment in 2013 50% 4
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 4%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
46% (42–51)
TB financing, 2016  
National TB budget (US$ millions) 13
Funding source: 40% domestic, 30% international, 30% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-06 Data: www.who.int/tb/data